Key result
Editorial explores high-dose perioperative statins to mitigate acute kidney injury following cardiac surgery.
Why the study?
Acute kidney injury is common after cardiac surgery and is associated with increased morbidity, mortality, and risk of chronic kidney disease, necessitating strategies to ameliorate it.
AKI after cardiac surgery demands clinical attention; editorial leaves open high-dose statin role, requiring randomized trials.
Acute kidney injury (AKI) is relatively common in the patients undergoing cardiac surgery. Over the past decade, several consensus definitions (namely the RIFLE, AKIN and KIDGO) have been developed to provide uniform criteria for the diagnosis of AKI, in order to facilitate comparisons between studies and the development of quantitative research (1-3). The incidence of AKI after cardiac surgery differs slightly depending on the classification criteria, ranging from 31–46% (3-5). It is well known that patients who developed AKI after cardiac surgery are at an increased risk of short-term and long-term morbidity and mortality. These patients tend to have higher mortality rates, prolonged ICU and hospital stay (5-7). These patients also have an increased risk of subsequent developing chronic kidney disease (CKD), which is associated with a higher long-term mortality (8).
No takes yet. Share an insight, caveat, or question.
Ngu et al. (2016) conducted an editorial in Acute kidney injury following cardiac surgery. High dose perioperative statins was evaluated. This editorial discusses the incidence and consequences of acute kidney injury following cardiac surgery, exploring the potential role of high-dose perioperative statins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: